MSB 3.21% $1.13 mesoblast limited

Ruxolitinib passed FDA approval on poorer single arm study results than Ryconcil, page-7

  1. 938 Posts.
    lightbulb Created with Sketch. 6
    I had a feeling this would happen, FDA in collusion with big pharma will nitpick MSB for as long as it takes to get rid of this pesky upstart
    I hope I'm wrong here, but looking at how all the alphabet institutions function over there,they are all compromised.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.